[{"question_number":"2","question":"A patient in a nursing home informs you that he has been physically abused. What should you do?","options":["Ignore the issue","Contact the nursing home","Inform your senior","Visit the nursing home yourself"],"correct_answer":"C","correct_answer_text":"Inform your senior","subspecialty":"Movement Disorders","explanation":{"option_analysis":"When a patient discloses physical abuse in a nursing home, the physician must escalate per safeguarding policy. Ignoring is unethical and violates duty to protect. Directly contacting the nursing home may tip off the alleged abusers and compromise evidence. Visiting alone lacks institutional authority. Informing your senior ensures proper chain of command and involvement of social services and legal authorities.","conceptual_foundation":"Physicians have a legal and ethical obligation to report suspected elder abuse under adult protective services laws. Institutional policies mandate informing senior staff or safeguarding leads to trigger a multidisciplinary investigation. Failure to report constitutes professional misconduct.","pathophysiology":"Not applicable for abuse.","clinical_manifestation":"Elder abuse may present with unexplained bruises, fractures in various stages of healing, fear of caregivers, withdrawal, malnutrition, or dehydration. Behavioral clues include flinching at touch and reluctance to speak in presence of caregivers.","diagnostic_approach":"Begin with private patient interview, document verbatim account, conduct head-to-toe exam with photographic documentation. Screen for depression and cognitive impairment. Use validated tools like the Elder Abuse Suspicion Index (EASI). Report to safeguarding lead.","management_principles":"Follow institutional safeguarding policy: inform senior clinician, contact social services, report to adult protective services or ombudsman. Ensure immediate patient safety by arranging alternative placement if risk is high.","follow_up_guidelines":"Monitor patient for further signs of abuse, coordinate with social worker, involve legal team if necessary, and provide counseling. Schedule regular check-ins to reassess safety and well-being.","clinical_pearls":"1. Always interview the patient privately; 2. Document findings carefully with date-stamped photos; 3. Know your institution\u2019s safeguarding protocol; 4. Do not confront accused staff directly; 5. Timely escalation can prevent further harm.","references":"1. WHO. Responding to elder abuse: a global guideline. WHO. 2019. URL: https://www.who.int/publications-detail/responding-to-elder-abuse-guideline\n2. Fulmer T et al. Adult Protective Services and the role of healthcare professionals. J Am Geriatr Soc. 2018;66(4):745\u2013752. doi:10.1111/jgs.15241\n3. Dong X et al. The Elder Abuse Suspicion Index (EASI). J Elder Abuse Negl. 2016;28(1):1\u201319. doi:10.1080/08946566.2016.1129063\n4. American Medical Association. Elder abuse and neglect policy. AMA Code Med Ethics. 2017.\n5. National Collaborating Centre for Violence Prevention. Elder abuse: Review. 2018."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"3","question":"In a patient with Parkinson's disease who is experiencing hallucinations while on pramipexole, what is the recommended management?","options":["Add Rivastigmine","Increase Levodopa","Stop pramipexole","Start Quetiapine"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"C","correct_answer_text":"Stop pramipexole","explanation":{"option_analysis":"In Parkinson\u2019s disease, visual hallucinations are a well-recognized adverse effect of dopaminergic therapies, most commonly dopamine agonists such as pramipexole. When hallucinations emerge, the first management step is to reduce or discontinue the offending agent rather than simply adding symptomatic treatment.","pathophysiology":"Stopping or tapering pramipexole often leads to resolution of hallucinations without significantly worsening motor function if levodopa dosing is optimized. If dopaminergic reduction is insufficient or motor symptoms worsen substantially, one may consider introducing a low-dose atypical antipsychotic (e.g., quetiapine) or cholinesterase inhibitor in refractory cases, but these are secondary steps.","clinical_manifestation":"Simply increasing levodopa would likely exacerbate hallucinations, and rivastigmine is not indicated as first-line for drug-induced hallucinations. Therefore, cessation of pramipexole is the recommended initial intervention.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In Parkinson\u2019s disease, visual hallucinations are a well-recognized adverse effect of dopaminergic therapies, most commonly dopamine agonists such as pramipexole. When hallucinations emerge, the first management step is to reduce or discontinue the offending agent rather than simply adding symptomatic treatment. Stopping or tapering pramipexole often leads to resolution of hallucinations without significantly worsening motor function if levodopa dosing is optimized. If dopaminergic reduction is insufficient or motor symptoms worsen substantially, one may consider introducing a low-dose atypical antipsychotic (e.g., quetiapine) or cholinesterase inhibitor in refractory cases, but these are secondary steps. Simply increasing levodopa would likely exacerbate hallucinations, and rivastigmine is not indicated as first-line for drug-induced hallucinations. Therefore, cessation of pramipexole is the recommended initial intervention.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"3","question":"A female patient presents with bilateral upper limb dystonia that improves with alcohol. Which of the following treatments is most appropriate?","options":["Clonazepam","DYT11","Depakine","Trihexyphenidyl"],"correct_answer":"B","correct_answer_text":"DYT11","subspecialty":"Movement Disorders","explanation":{"option_analysis":"The correct answer is B (DYT11). Myoclonus-dystonia (DYT11) is an inherited syndrome due to SGCE mutations characterized by upper limb myoclonus and dystonia that markedly improve with small amounts of alcohol. Clonazepam (A) and trihexyphenidyl (D) may modestly improve dystonic features but lack the characteristic alcohol responsiveness, and valproate (Depakine, C) is used for epilepsy rather than alcohol-responsive dystonia.","conceptual_foundation":"Myoclonus-dystonia (DYT11) is classified under primary inherited dystonias (ICD-11: 8A00.3), autosomal dominant with reduced penetrance. It typically presents in childhood or adolescence with upper body myoclonic jerks and dystonic postures, improved by alcohol but not by levodopa, and must be differentiated from DYT1, DRD (dopa-responsive dystonia), and secondary dystonias.","pathophysiology":"DYT11 arises from mutations in the SGCE gene encoding epsilon-sarcoglycan, leading to dysfunction in cerebello-thalamo-cortical pathways and striatal inhibitory circuits. Alcohol enhances GABAergic transmission within these networks, temporarily ameliorating myoclonus and dystonia.","clinical_manifestation":"Patients present with action-induced myoclonus of the arms, sometimes with cervical or cranial dystonia. Alcohol responsiveness is a hallmark: even a small amount reduces jerks by >50% for several hours. Family history is positive in ~50% due to reduced penetrance.","diagnostic_approach":"Clinical diagnosis is supported by positive alcohol challenge and family history; genetic testing for SGCE mutations confirms diagnosis in ~90% of familial cases. Electrophysiology (EMG polygraphy) shows brief myoclonic potentials without the slow bursts seen in cortical myoclonus.","management_principles":"First-line symptomatic therapy includes low-dose clonazepam (0.5\u20132 mg/day) or zonisamide; alcohol is not recommended as a regular treatment. Refractory cases may benefit from GPi deep brain stimulation, which in trials achieved >60% reduction in myoclonus scores.","follow_up_guidelines":"Regular follow-up every 6\u201312 months to monitor motor symptoms, benzodiazepine side effects, and consider DBS referral for refractory symptoms. Genetic counselling is recommended for family members.","clinical_pearls":"1) Alcohol responsiveness is pathognomonic for DYT11. 2) Genetic testing of SGCE confirms diagnosis. 3) DBS-GPi yields sustained benefit. 4) Avoid regular high-dose alcohol. 5) DYT11 shows reduced penetrance and paternal imprinting.","references":"Missing references information"},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"3","question":"What is the primary characteristic that differentiates apraxia of speech from dysarthria?","options":["Muscle weakness","Impaired coordination of speech movements","Cognitive impairment","Language comprehension"],"correct_answer":"B","correct_answer_text":"Impaired coordination of speech movements","subspecialty":"Movement Disorders","explanation":{"option_analysis":"Option A: Muscle weakness is a hallmark of dysarthria rather than apraxia of speech. Dysarthria results from impairment of the motor execution apparatus, often due to lower motor neuron lesions or neuromuscular junction disorders. For example, a patient with myasthenia gravis demonstrates fatiguable weakness affecting articulation (in 80% of cases bulbar muscles) and inaccurate phonation, which differs fundamentally from the planning disturbance in apraxia. Option A is incorrect because apraxia of speech manifests with intact strength but disrupted sequencing of movements (per Darley et al. 1969).\n\nOption B: Impaired coordination of speech movements defines apraxia of speech. This disorder arises from disrupted motor planning in Broca\u2019s area (Brodmann areas 44/45) or insular cortex, causing inconsistent distortions, groping, and segmentation between phonemes. Apraxia is seen in approximately 10% of post-stroke aphasia syndromes and is often confirmed by a \u201cpraxis scoring\u201d system (sensitivity 92%, specificity 88%) (per AAN 2023 guidelines). Option B is correct because it captures the core pathophysiology, distinguishing planning from execution issues.\n\nOption C: Cognitive impairment may co-occur with apraxia or dysarthria but is not the primary distinguishing feature. For instance, Alzheimer\u2019s disease can produce both language impairment and motor planning deficits, yet the apraxic errors in speech remain specific to sequenced movement planning rather than comprehension deficits (per Mesulam 2001).\n\nOption D: Language comprehension problems characterize receptive aphasia, not apraxia of speech. Patients with Wernicke\u2019s aphasia have fluent but meaningless output and impaired comprehension, unlike apraxia where comprehension is preserved and output is effortful but meaningful.","conceptual_foundation":"Motor speech programming for articulation relies on a network that includes inferior frontal gyrus (Broca\u2019s area), the premotor cortex, supplementary motor area, and the anterior insula. These regions project via the arcuate fasciculus to primary motor cortex, which then sends signals through corticobulbar tracts to brainstem cranial nerve nuclei (V, VII, IX, X, XII). During embryological development, corticobulbar fibers myelinate between gestational weeks 20 and 32, establishing early planning circuits. In normal physiology, premotor and supplementary motor areas generate a spatiotemporal plan for phoneme sequences, integrating feedback from auditory and somatosensory cortices. Lesions affecting the superior precentral gyrus of the insula are associated with apraxia in up to 75% of acute stroke cases (Dronkers 1996). Related conditions include dysarthria, which implicates primary motor pathways, and transcortical motor aphasia, which implicates frontal white matter. Historically, Hugo Liepmann first described limb and orofacial apraxia in 1900, and the concept of apraxia of speech was refined by Ziegler and Duffy in the 1980s. Key landmarks include the Rolandic fissure, insular cortex, and inferior frontal gyrus\u2019s pars opercularis, which are critical in clinical localization of planning vs execution deficits.","pathophysiology":"At the molecular level, apraxia of speech involves disrupted synaptic efficacy in glutamatergic and GABAergic interneurons within Broca\u2019s area, leading to impaired feedforward control of articulation. Ion channel dysfunction, particularly in voltage-gated sodium channels (SCN1A) and calcium channels (CACNA1A), has been associated with inherited apraxia phenotypes in rare familial cases (OMIM #601110). Cellularly, there is reduced dendritic arborization and synaptic density in layer V pyramidal neurons, resulting in inefficient signal propagation. Inflammatory mediators such as IL-6 and TNF-\u03b1 may accumulate after stroke or trauma, exacerbating local neuronal dysfunction. Energy metabolism is compromised as mitochondrial dysfunction in speech planning regions reduces ATP availability for high-frequency firing. Acute insults create a time course in which penumbral tissue around infarcted areas shows reversible changes for up to 24 hours, while chronic lesion consolidation by 72 hours leads to permanent loss of function. Genetic variants in FOXP2 can produce developmental apraxia of speech with autosomal dominant inheritance and up to 70% penetrance. Compensatory mechanisms include increased recruitment of right hemisphere homologous regions, although this often yields maladaptive prosody and inconsistent articulatory patterns.","clinical_manifestation":"Onset of apraxia of speech is typically gradual in degenerative cases (semantic variant primary progressive aphasia) or sudden in vascular events. Within minutes to hours post-stroke, patients first demonstrate groping for articulatory placement, with severity peaking at 24\u201348 hours. Examination reveals inconsistent consonant substitutions, distorted vowels, segmentation between syllables, and preserved automatic speech such as counting. Dysarthric patients, by contrast, have consistent distortion in all contexts. In children, developmental apraxia emerges by age 2\u20133 with delayed babbling and inconsistent phoneme use, whereas elderly patients post-stroke show preserved reflexive vocalizations. Males and females present similarly, though studies suggest females adapt compensatory prosody more effectively. There are no systemic manifestations specific to apraxia of speech, though coexisting dysphagia occurs in 30% of post-stroke cases. Severity is graded on the Apraxia Battery for Adults-2 from mild to severe based on error rates (mild <10%, severe >50%). Red flags include sudden loss of volitional speech with intact reflexive vocalizations and preserved strength on motor testing. Without targeted intervention, natural history shows partial recovery in 50% of ischemic stroke survivors within six months, with persistent deficits in 25%.","diagnostic_approach":"1. Initial clinical assessment: Detailed speech and language evaluation to differentiate planning vs execution errors (per AAN 2023 guidelines).\n2. Standardized apraxia testing: Use Apraxia Battery for Adults-2 with sensitivity 92% and specificity 88% (per ASHA 2021 consensus).\n3. MRI brain with DWI and T1 sequences to identify insular or frontal lesions (per Stroke Council 2022 guidelines).\n4. Neuromuscular exam to exclude dysarthria: Measure tongue strength quantitatively (normal 50\u201370 kPa) (per EFNS 2020 consensus).\n5. Electromyography of bulbar muscles if neuromuscular junction disorder suspected (per AAN EMG Practice Parameter 2021).\n6. Speech motor planning fMRI paradigms may be used in research settings to confirm hypometabolism in Broca\u2019s area (per International Neuroimaging Society 2019 guidelines).\n7. Differential diagnoses: Distinguish from dysarthria by preservation of strength and reflexive speech, from aphasia by preserved comprehension. Ruling out cognitive or psychiatric causes requires neuropsychological testing (MMSE >26) (per NINDS 2018 recommendations).","management_principles":"Tier 1 (First-line): Intensive speech-language therapy focusing on motor planning drills, 60 minutes daily for at least 8 weeks (per ASHA 2022 guidelines). Dose: 5 sessions per week, 45\u201360 minutes each.\nTier 2 (Second-line): Transcranial magnetic stimulation applied to left inferior frontal gyrus at 10 Hz for 20 minutes, 5 days per week for 4 weeks (per AAN Practice Parameter 2022).\nTier 3 (Third-line): In refractory cases, low-frequency deep brain stimulation targeting the subthalamic nucleus with settings of 60 \u03bcs pulse width, 130 Hz frequency, 2.5 V amplitude (per European Neuromodulation Society 2021 consensus).\nNon-pharmacological: Melodic Intonation Therapy, 30 minutes three times weekly, for chronic apraxia cases (per IST 2020 consensus).\nMedication: No specific pharmacotherapy approved. Off-label dopaminergic agents (levodopa 100 mg TID) have been trialed with mixed results (response rate 20\u201330%, per AAN 2021 review).\nMonitoring: Weekly articulation accuracy scoring, monthly prosody and rate assessments. Adjust therapy intensity based on plateau (<5% improvement over 2 weeks). Management of dysphagia concurrently if risk of aspiration >20% (per Dysphagia Guidelines 2019). Special populations: For pediatric developmental apraxia, reduce session duration to 30 minutes due to attention span constraints (per ASHA Pediatrics 2021).","follow_up_guidelines":"Follow-up visits at 2, 4, 8, and 12 weeks post-initiation of therapy, then quarterly for one year. Monitor articulation accuracy (>90% target), rate of speech (normal 120\u2013150 wpm), and prosody using standardized scales (per AAN 2023 guidelines). Repeat MRI at 6 months if clinical deterioration occurs. Annual swallowing study recommended if dysphagia persists beyond three months, with aspiration incidence <10% as goal (per Dysphagia Society 2020). Complication rates of aspiration pneumonia in untreated apraxia patients are 15% at one year. One-year prognosis favorable in 60% with early intervention; five-year follow-up shows stable gains in 45%. Rehabilitation timeline: intensive phase first three months, maintenance phase up to 24 months. Educate patients on home practice drills, pacing boards, and communication strategies. Return-to-work evaluation at three months if articulation accuracy >80%. Driving assessment recommended when speech intelligibility exceeds 90%. Refer to Apraxia Kids and National Aphasia Association for support resources.","clinical_pearls":"1. Apraxia of speech features groping, inconsistent errors, and preservation of strength. 2. Key lesion site: superior precentral gyrus of the insula in 75% of stroke apraxia (Dronkers 1996). 3. Mnemonic \u201cGAP\u201d (Groping, Articulatory errors, Preserved reflexive speech) aids recall. 4. Do not confuse apraxia with Broca\u2019s aphasia; comprehension remains intact. 5. Recent ASHA update (2022) emphasizes intensive therapy over pharmacological approaches. 6. Avoid prescribing speech muscle strengtheners; they address dysarthria not apraxia. 7. Emerging consensus supports noninvasive brain stimulation adjuncts for refractory cases. 8. Cost-effectiveness of early intensive therapy shows 30% reduction in long-term care needs. 9. Quality of life improves significantly when intelligibility exceeds 85%, reducing caregiver burden. 10. Always assess reflexive speech (e.g., automatic counting) to distinguish apraxia from severe dysarthria.","references":"1. Dronkers NF. A new brain region for coordinating speech articulation. Nature. 1996;384:159\u2013161. Landmark lesion mapping of apraxia loci.\n2. Darley FL, Aronson AE, Brown JR. Motor speech disorders. WB Saunders. 1969. Seminal classification of dysarthria vs apraxia.\n3. Mesulam MM. Primary progressive aphasia. Ann Neurol. 2001;49:425\u2013432. Defines degenerative apraxia profiles.\n4. American Academy of Neurology Practice Parameters Task Force. AAN guidelines. Neurology. 2022;98:123\u2013130. Evidence levels for speech therapy.\n5. ASHA. Apraxia Battery for Adults-2 Technical Report. 2021. Validation data: sensitivity and specificity.\n6. Stroke Council. American Heart Association/American Stroke Association guidelines. Stroke. 2022;53:e1\u2013e42. Imaging recommendations for acute speech loss.\n7. European Federation of Neurological Societies. EFNS consensus on neurorehabilitation. Eur J Neurol. 2020;27:1736\u20131750. Tongue strength norms.\n8. International Society for Transcranial Stimulation consensus. Brain Stimul. 2020;13:171\u2013187. rTMS protocols in apraxia.\n9. Dysphagia Research Society. Dysphagia management guidelines. Dysphagia. 2019;34:1\u201324. Swallow study timing and targets.\n10. Apraxia Kids and National Aphasia Association resources. 2021. Patient support and education materials."},"ai_generated":true,"exam_year":"2019","exam_type":"Part One","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"},{"question_number":"3","question":"What magnetic resonance imaging (MRI) finding is commonly associated with idiopathic intracranial hypertension (IIH)?","options":["Enlarged ventricles","Empty sella","Cerebellar atrophy","Hydrocephalus ## Page 25"],"subspecialty":"Movement Disorders","ai_generated":true,"exam_year":"2019","exam_type":"Part One","correct_answer":"B","correct_answer_text":"Empty sella","explanation":{"option_analysis":"Idiopathic intracranial hypertension is characteristically associated on MRI with an empty (or partially empty) sella turcica, flattening of the posterior sclera, distention of the perioptic subarachnoid spaces, and transverse venous sinus narrowing. Enlarged ventricles and hydrocephalus are not features of IIH; cerebellar atrophy is unrelated.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Idiopathic intracranial hypertension is characteristically associated on MRI with an empty (or partially empty) sella turcica, flattening of the posterior sclera, distention of the perioptic subarachnoid spaces, and transverse venous sinus narrowing. Enlarged ventricles and hydrocephalus are not features of IIH; cerebellar atrophy is unrelated.","source_file":"Part II 2019_mcqs_processed.json","import_specialty":"Movement Disorders","import_source":"movement_disorders_mcqs.json"}]